Clinical Safety of a Novel Milk Protein Peptide

Completed · Phase 1 · Has a placebo group

Conditions studied: Drug Safety

In brief

Background: A novel milk peptide has been shown in laboratory setting to have natural anti-cancer properties and extend lifespan and improve metabolism in animal models. The purpose of this study was 1.) to determine the safety dosage range and, 2.) to determine whether this novel milk peptide positively influence blood markers, metabolism and improve quality of life.

Key facts

Study ID

NCT01412658

Run by

Ambryx Biotechnology

People needed

73

Starts

2006-11-01

Expected to finish

2007-02-01

Last updated by the study team

2011-08-09

Who can join

Age: 35 and older, up to 60. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy subjects with body mass index between 27-40.

You may not qualify if…

• have any metabolic disorders including known electrolyte abnormalities, heart disease, arrhythmias, diabetes, thyroid disease or hypogonadism; a history of hypertension, hepatorenal, musculoskeletal, autoimmune, or neurologic disease; if they are taking thyroid, hyperlipidemic, hypoglycemic, anti-hypertensive, or androgenic medications;
• have milk allergies

Where it is running

• Baylor University Center for Exercise, Nutrition, and Preventive Health Research — Waco, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.